ROCKVILLE, Md., July 24 /PRNewswire/ -- Panacea Pharmaceuticals, Inc.
announced today the presentation of three papers at the 8th International
Conference on Alzheimer's Disease & Related Disorders in Stockholm, Sweden.
The conference is the largest-ever global gathering of Alzheimer's scientists,
and is hosted by the Alzheimer's Association.
The three presented papers were as follows:
INCREASED OXIDATIVE STRESS INVOLVING OLFACTORY NEURONS IN ALZHEIMER
DISEASE
Hossein Ghanbari, Zvezdana Kubat, Kasra Ghanbari, Massimo Tabaton, Rudy J.
Castellani, Mark A. Smith, George Perry
THE EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTORS PREDICTS NEURONAL
VULNERABILITY IN ALZHEIMER'S DISEASE
Hyoung-gon Lee, Osamu Ogawa, Xiongwei Zhu, Rudolph J. Castellani, Hossein
Ghanbari, George Perry, Mark A. Smith, Catherine Rottkamp
DUAL TRACER EMISSION COMPUTED TOMOGRAPHY (DTECT): A PRACTICAL NEW
TECHNIQUE FOR THE DIFFERENTIAL DIAGNOSIS, STAGING AND MONITORING OF DEMENTIA
Christopher Kircher, Hossein A. Ghanbari, Harold T. Pretorius
The abstracts can be viewed online at
http://www.alz.org/internationalconference/abstracts.htm .
Hossein A. Ghanbari, Ph.D., President and CEO of Panacea stated, "These
findings continue to support the use of our proprietary models for drug
discovery and development. The goal of our program is to build a highly
integrated technology portfolio based on neuroprotection and aimed at
abnormalities relevant to the etiology of the disease and not simply the
clinical or histopathological symptoms."
Panacea's Integrated, Multi-Technology Program
The Company has previously announced the licensing of technology from two
groups of researchers at Case Western Reserve University in Cleveland, Ohio
covering oxidative stress and cell cycle abnormalities in neurodegenerative
diseases, particularly AD, as well as a collaboration with researchers at
Brown University/Rhode Island Hospital to develop drugs to prevent and treat
oxidative stress induced neurodegeneration in a number of conditions including
Alzheimer's disease.
The first collaboration at CWRU covers the role of oxidative stress in
neurodegenerative diseases. Brain tissue studies have clearly demonstrated
that the affected neurons in AD brains are more prone to oxidative stress as
indicated by increased level of oxidative stress markers. The Company and its
collaborators have developed several proprietary in vitro model for studying
oxidative stress in AD-derived cells versus normal as well as for screening
compounds that protect neurons prone to oxidative stress. Recent findings were
published in the Journal of Neuropathology and Experimental Neurology (Vol.
60, page 504).
The second collaboration at CWRU covers cell cycle abnormalities in
neurodegenerative diseases. Neuronal cells in the brain do not normally
divide. However, it has been demonstrated that, in AD brains, some neurons
begin to divide without being able to go through various phases of cell
division. These cells are prone to oxidative stress and degenerate readily.
The Company and its collaborators have developed a proprietary in vitro model
for high-throughput screening of compounds aimed at protecting the neurons as
well as for studying the mechanism of cell cycle involvement in
neurodegeneration and finding a molecular target for developing drugs for AD
and other neurodegenerative diseases. These findings were published in two
articles in Neurobiology of Aging (Vol. 21, No. 6, pages 807-813 and 837-841).
The Company and its collaborators at Brown University are exploring new
and novel discoveries towards determining the mechanisms of oxidative injury
mediated neuronal impairment and neuronal cell death. The collaboration
utilizes proprietary in vitro and in vivo models that allow high-throughput
screening to identify drug candidates that would be used to either prevent the
onset or reduce the progression of neuronal degeneration caused by oxidative
damage.
About Panacea Pharmaceuticals
Panacea Pharmaceuticals, Inc. is an emerging biopharmaceutical company
focused on utilizing functional genomics and proteomics to develop
therapeutics and diagnostics for diseases with substantial unmet clinical
need. The Company's product development focus is on novel proteins and
biochemical pathways related to cellular regulation and cell cycle
abnormalities in oncology as well as neurodegenerative diseases, particularly
Alzheimer's disease and Parkinson's disease.
More information is available at http://www.PanaceaPharma.com .
Except for historical information presented in this press release, matters
discussed herein may constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements are based on the opinions and estimates of management only
as of the date of this release and are subject to certain risks and
uncertainties that could cause actual results to differ materially from any
future results, performance, or achievements expressed or implied by such
statements. Factors that might cause such a difference include, but are not
limited to, uncertainties related to our access to capital, the progress,
costs, and results of any clinical trials undertaken by us, progress of our
research and development projects, and uncertainties related to whether our
product candidates would ultimately achieve commercial success. We do not
undertake any obligation to update publicly any forward-looking statement,
whether as a result of new information, future events, or otherwise unless
required by law.
CONTACT: Kasra Ghanbari, Chief Operating Officer, of Panacea
Pharmaceuticals, Inc., +1-240-453-6295, or fax, +1-240-465-0450, or
Kasra@PanaceaPharma.com
SOURCE Panacea Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panaceapharma.com
http://www.alz.org/internationalconference/abstracts.htm
CONTACT:
Kasra Ghanbari, Chief Operating Officer,
Panacea Pharmaceuticals, Inc., +1-240-453-6295, or fax,
240-465-0450, or Kasra@PanaceaPharma.com
|
